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Erbicin is a human anti-ErbB2 single-chain antibody fragment with high affinity and selectivity for ErbB2-positive cancer cells. Two anti-
ErbB2 immunoconjugates, called Erb-hRNase and Erb-hcAb, have been prepared and found to be selectively cytotoxic on ErbB2-
positive cancer cells in vitro and vivo. In Erb-hRNase, Erbicin is linked to a human RNase and in Erb-hcAb it is linked to the key
structural and functional regions of a human IgG. Herceptin is an anti-ErbB2 humanised antibody successfully used in the
immunotherapy of breast cancer. We report here that the Erbicin-derived immunoagents target on breast cancer cells an ErbB2
epitope different than that of Herceptin. This finding led us to verify the effects of Herceptin on breast cancer cells when it was used
in combination with the Erbicin-derived immunoagents. The results indicated that in combination experiments the antitumour action
of Herceptin and that of the novel agents were significantly increased in an additive fashion. An inspection of the mechanism of action
of Erb-hRNase or Erb-hcAb combined with Herceptin provided evidence that the antibody combinations engendered an increased
downregulation of the ErbB2 receptor, and led to an enhanced apoptotic cell death.
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Breast cancer is the second most common female cancer world-
wide. The major molecule implicated as a contributing cause for
this malignancy is the transmembrane tyrosine kinase ErbB2
receptor. Its overexpression is a prognostic predictor of overall
survival and time to relapse (Cooke et al, 2001). However,
amplification of the HER2/neu (ErbB2) gene, and overexpression
of the receptor occurs in only a fraction (up to 25%) of invasive
breast cancers.
Herceptin, the only anti-ErbB2, humanised monoclonal anti-
body approved by FDA for therapy of mammary carcinoma is
currently and successfully prescribed for treatment of ErbB2-
positive breast cancer. However, in 40–60% of all patients with
ErbB2-overexpressing tumours (Cardoso et al, 2002), Herceptin
has little or no effect on tumour regression. For these patients, the
prognosis is poor and the disease progresses more aggressively. To
increase the response rate, combination treatments of Herceptin
with anthracyclines have been performed, but unfortunately this
leads to the onset of heart failure and cardiomyopathy. In fact,
large-scale clinical studies with Herceptin have shown that up to
7% of patients suffer from cardiac disfunction when Herceptin
is used in monotherapy, and 28% when it is combined with
anthracyclines (Baselga, 2000; Slamon et al, 2001; Sparano, 2001).
These facts indicate that novel immunotherapeutic strategies to
fight ErbB2-positive carcinomas are strongly called for.
We have isolated Erbicin, a human anti-ErbB2 scFv (single-
chain antibody fragment) (De Lorenzo et al, 2002), and used it to
prepare two immunoconjugates. The first of these was a fully
human anti-ErbB2 immunoRNase, called Erb-hRNase (De Lorenzo
et al, 2004a), in which the toxin of a typical immunotoxin is
replaced by a pro-toxin, a nontoxic human RNase. The RNase
however becomes toxic when internalised in ErbB2-positive
tumour cells, to which it is directed through its fusion with
Erbicin. Another Erbicin-derived immunoconjugate was a human,
compact antibody (De Lorenzo et al, 2004b) called Erb-hcAb. It
was obtained by fusing human Erbicin to the CH2, CH3 and hinge
regions from a human IgG1. Such antibody is described as
‘compact’ for its reduced size (100kDa) when compared to that of
a typical IgG (155kDa).
Both immunoconjugates, Erb-hRNase and Erb-hcAb, were
found to have a high affinity for ErbB2 with an apparent KD in
the nM range and selectively kill ErbB2-positive cells, both in vitro
and in vivo (De Lorenzo et al, 2004a,b, 2005), with no detectable
effects on ErbB2-negative cells. The Erb-hcAb antibody has been
found to possess, in contrast to Herceptin, not only antigen-
dependent (ADCC) but also complement-dependent (CDC)
cytotoxicity. Furthermore, its size, smaller than that of immuno-
globulins, should favour penetration in solid tumours.
Here we show for the first time that these novel immunoagents
recognise on the ErbB2 receptor an epitope different from that
targeted by Herceptin. Based on this finding, we demonstrate that
the novel anti-ErbB2 immunoagents can be successfully used in
combination with Herceptin, and with conventional antineoplastic
agents, such as taxol and cis-platin, to achieve more potent
antitumour effects.
MATERIALS AND METHODS
Antibodies and cell cultures
The antibodies used were: Herceptin (Genentech, South San
Francisco, CA, USA); HRP-conjugated anti-His antibody (Qiagen,
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sValencia, CA, USA); horseradish peroxidase-conjugated goat anti-
human affinity isolated IgG (Fc specific) (Sigma, St Louis, MO,
USA); horseradish peroxidase-conjugated rabbit anti-mouse im-
munoglobulin antibody (Pierce, Rockford, IL, USA). Erbicin, Erb-
hcAb and Erb-hRNase were prepared as previously described (De
Lorenzo et al, 2004a,b).
SKBR3 cells (from ATCC, Rockville, MD, USA) were cultured in
RPMI 1640 (Gibco BRL, Life Technologies, Paisley, UK) with 10%
foetal bovine serum, 50Uml
 1 penicillin and 50mgml
 1 strepto-
mycin (all from Gibco BRL). Hybridomas producing 7c2, MAB74
and 2c4 mAbs (ATCC) were grown in a 1:1 mixture of DMEM
(Gibco) and RPMI 1640 supplemented with 10% heat-inactivated
foetal bovine serum.
Enzyme-linked immunosorbent assays
ErbB2-positive SKBR3 cells, harvested in nonenzymatic dissocia-
tion solution (Sigma), were washed and transferred to U-bottom
microtitre plates (1 10
5 cells per well). After blocking with PBS
containing 6% bovine serum albumin (BSA), cells were treated
with the antibodies in enzyme-linked immunosorbent assay
(ELISA) buffer (PBS/BSA 3%) for 90min. After centrifugation
and removal of supernatants, the pelleted cells were washed twice
in 200ml of ELISA buffer, resuspended in 100ml of ELISA buffer,
and incubated with peroxidase-conjugated anti-His mAb (Qiagen)
for scFv detection, with peroxidase-conjugated anti-human IgG
(Fc-specific) antibody (Sigma) or peroxidase-conjugated anti-
mouse IgG antibody (Pierce) for detection of human or murine
antibodies, respectively. After 1h, the plates were centrifuged,
washed with ELISA buffer, and reacted with 3,30,5,50-tetramethyl-
benzidine (TMB) (Sigma). Binding values were determined from
the absorbance at 450nm, and reported as the mean of at least
three determinations (standard deviationp5%).
Cell morphology and apoptosis as induced by anti-ErbB2
antibodies
SKBR3 cells were plated at a density of 6 10
5 well
 1 in six-well
plates and incubated at 371C with either Herceptin (200nM)o r
Erb-hcAb (200nM) or with both antibodies simultaneously for
24–72h. These concentrations were chosen to achieve maximal
effects. After suitable time intervals, cells were harvested, washed
in PBS, and treated with Annexin V-FITC following resuspension
in binding buffer (10mM HEPES, pH 7.4, 140mM NaCl, 2.5mM
CaCl2). Labelled cells were analysed using the FACS Calibur flow
cytometer (Becton Dickinson, Oxford, UK); the data were
processed using CellQuest software (Becton Dickinson). The
apoptotic inducer puromycin (10mgml
 1) was used as a positive
control. After 72h, cells from plates cultured in parallel were
observed by light microscopy (Nikon ECLIPSE E1000, Melville,
NY, USA), photographed (Nikon digital camera DXM 1200F),
detached from the plates with cell dissociation solution (Sigma)
and counted using the Trypan-Blue (Sigma) exclusion test.
Cytotoxicity assays
ErbB2-positive cells were seeded in 96-well plates at a density of
1.5 10
4well
 1 in 150ml. For the evaluation of the effects achieved
by combining the chemotherapeutic drugs with the immuno-
agents, Taxol (Bristol-Myers Squibb, Sermoneta, Italy) or cis-platin
(Sigma) were added at increasing concentrations in the presence or
absence of Erb-hcAb (100nM) or Erb-hRNase (10nM).
For combinatorial treatment with Herceptin, given the lower
cytotoxic effect of Herceptin, higher concentrations of Erbicin-
derived immunoagents were used. Thus, cells were treated with
Erb-hcAb (120nM), Erb-hRNase (25nM) or with a combination of
each immunoagent with Herceptin (120nM). After 72h at 371C, cell
viability was determined in triplicate using the ATPlite 1 step test
(Perkin Elmer, Cologno Monzese, Italy). The resulting lumines-
cence was measured in a microplate counter (Multilabel Counter
Victor 3, Perkin Elmer). Cell survival was expressed as percent of
viable treated cells with respect to control untreated cultures.
Typically, standard deviations were below 5%.
Receptor downregulation assay
SKBR3 cells were plated at a density of 6 10
5 well
 1 in six-well
plates. After 24h, the medium was replaced by methionine-free
medium containing 100mCi of [
35S]methionineml
 1 in 2% foetal
bovine serum. Cells were metabolically labelled for 16h and then
incubated with Erb-hcAb or Herceptin (each at a concentration of
200nM) or with both antibodies in fresh medium containing
unlabelled methionine. After 16h, whole-cell lysates were prepared
and equal amounts, determined by radioactivity measurement,
were subjected to immunoprecipitation with the C-terminal-
specific anti-ErbB2 antibody Neu C-18 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) and with an anti-actin mAb (Sigma). The
immune complexes were collected by adsorption to protein A-
Sepharose beads (Sigma) for 1h at 41C, then washed and released
by boiling in electrophoresis loading buffer. Samples were
separated on a 7.5% SDS–PAGE, and analysed by autoradio-
graphy. Band intensities were quantitated by using a scanner
(Molecular Imager FX GS-710, Biorad, Hercules, CA, USA).
Surface plasmon resonance analyses
Studies on the binding properties of Herceptin, Erb-hcAb and Erb-
hRNase to the soluble ErbB2 receptor extracellular domain (ECD)
were performed by surface plasmon resonance spectroscopy using
a BIAcore X instrument (BiacoreAB, Uppsala, Sweden). Extra-
cellular domain was immobilised to the surface of sensor chip CM5
(Biacore, Inc., Piscataway, NJ, USA) using standard amine
coupling chemistry. During the coupling process, a constant flow
rate of 10mlmin
 1 was maintained. The surface of the chip was
activated with a 70ml mixture 1:1 of 0.4 M 1-ethyl-3-(3-dimethyl
aminopropyl) carbodimide hydrochloride and 0.1 M N-hydroxy-
succinimide (Biacore, Inc.), followed by 60ml of ECD (1mgml
 1)
dissolved in 10mM sodium acetate buffer, pH 4.5, to capture
500RU of ECD. To block unreacted activated esters, 70mlo f1 M
ethanolamine hydrochloride, pH 8.5, was finally injected, and the
remaining noncovalently associated ECD was washed from the
surface with four 30s injections of 10mM NaOH. The reference
flow cell was inactivated by amine coupling chemistry, as already
described without the ECD injection. The running buffer was HBS-
EP buffer (10mM HEPES with 0.15 M NaCl, 3.4mM EDTA and
0.005% surfactant P20 at pH 7.4). The binding analyses of Erb-
hcAb and Erb-hRNase to ECD immobilised on the surface were
performed by two subsequent injections of 213nM Erb-hcAb
(corresponding to 426nM binding site concentration) or 500nM
Erb-hRNase using a 2min contact time for each injection at a
constant flow rate of 5mlmin
 1. The concentrations of Herceptin,
Erb-hcAb and Erb-hRNase were chosen after several experiments
at different concentrations. For Herceptin, a saturating concentra-
tion was chosen; for the Erbicin-derived immunoagents, the
minimum concentration that gave clear effects was chosen.
Sensor chip surface was regenerated by a 30s injection of 25mM
NaOH/1M NaCl. Competition in binding to ECD between
Herceptin and Erb-hcAb or Erb-hRNase was investigated by
saturating the sensor chip with Herceptin and injecting over the
surface Erb-hcAb or Erb-hRNase. To this purpose, two subsequent
injections of 440nM Herceptin at a constant flow rate of 5mlmin
 1
were performed using 2min contact time for each injection,
followed by two subsequent injections of 213nM Erb-hcAb or
500nM Erb-hRNase using a 2min contact time for each injection.
No regeneration of sensor surface was made between injections.
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sRESULTS
The epitope recognised by Erbicin-derived immunoagents
is different from that of Herceptin
The apparent binding affinity of the compact antibody (Erb-hcAb)
for the ErbB2 receptor on SKBR3 cells, as measured with ELISA
assays, has been found to be about 1nM (De Lorenzo et al, 2004b).
This value is close to the values of 4 and 5nM reported in the same
paper for the parental Erbicin and Herceptin, respectively.
To determine if the novel immunoagents recognise an epitope
different from that targeted by Herceptin, competition experi-
ments were carried out by repeating the ELISA assays in the
presence of Herceptin.
In these experiments, the parental scFv (Erbicin) was added at
increasing concentrations (5–40nM) to ErbB2-positive cells
preincubated with Herceptin at a saturating concentration
(50nM) for 1h, or to untreated cells. Binding was detected with a
peroxidase-conjugated anti-His mAb capable to reveal the scFv.
As shown in Figure 1, the binding curves of Erbicin obtained in
the absence or presence of Herceptin were found to be super-
imposable. These results strongly suggest that the epitope
recognised by the scFv is different from that of Herceptin. This
would clearly apply also to the immunoconjugates (Erb-hcAb and
Erb-hRNase) in which Erbicin is the immunomoiety.
To test whether other available anti-ErbB2 monoclonal anti-
bodies such as 2c4 (Pertuzumab precursor), 7c2 and MAB74
recognise different epitopes from that of Erbicin-derived immuno-
agents, binding assays were performed by adding each mAb
preparation to SKBR3 cells previously incubated with Erb-hcAb at
a saturating concentration (50nM) for 1h, or to untreated cells.
The binding ability of all three mAbs, detected with a
peroxidase-conjugated anti-mouse secondary antibody (data not
shown), was unaffected by the presence of Erb-hcAb. These results
strongly suggest that the epitope recognised by the Erbicin-derived
compact antibody is different from that bound by the three
antibodies tested.
The competition, or lack of, between the Erb-hcAb and Erb-
hRNase immunoagents and Herceptin for binding to the ErbB2
ECD was then tested with plasmon resonance experiments. Erb-
hcAb and Erb-hRNase were each injected over ECD immobilised
on the chip, before and after saturation with Herceptin (Figure 2).
After the ECD surface was saturated by repeated injections with
Herceptin until no significant additional response was observed
(Figure 2), equivalent amounts of each immunoagent were injected
in parallel experiments. Both binding curves of Erb-hcAb and Erb-
hRNase were found to be similar to those obtained in the absence
of Herceptin (Figure 2, inset). This indicates that each immuno-
agent could bind to the ECD on the chip surface irrespective of the
previous saturation with Herceptin.
It should be noted that in the case of Herceptin, no signs of
dissociation were detectable. In the case instead of the Erbicin-
derived immunoagents, the dissociation phase is already evident at
about 120s, as soon as the washings started. This is likely due to
different koff values. In fact, the dissociation phase, when no
rebinding of analytes to the surface occurs, depends on the
dissociation rate constant (koff), but it is independent on the
association rate constant (kon).
In conclusion, both the results of the ELISA assays and those of
the plasmon resonance assays show that the novel immunoagents
do not compete with Herceptin for binding to ErbB2, and hence
they bind on a site different from that of Herceptin.
Effects on cell survival of Erbicin conjugates in
combination with Herceptin
It has been reported (Harwerth et al, 1993; Hurwitz et al, 1995) that
treatment with anti-ErbB2 antibodies that bind to different
domains of the ErbB2 receptor leads to antitumour effects more
potent than those observed when the cells are treated with each
antibody alone.
On the basis of the observation that Herceptin and Erbicin-
derived immunoagents bind to different epitopes on the receptor,
we compared the growth inhibition effects of the compact antibody
and the immunoRNase when administered alone or in combina-
tion with Herceptin.
ErbB2-positive cells were treated for 72h at 371C with Herceptin
(120nM), Erb-hcAb (120nM), Erb-hRNase (25nM) or with a
combination of each immunoagent with Herceptin at the same
concentrations. As shown in Figure 3, the combinatorial treatment
inhibited the growth of SKBR3 cells more effectively than the
treatment with each single immunoagent, thus showing additive
interactions.
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Figure 1 Binding curves of Erbicin to SKBR3 cells obtained through
ELISA assays performed in the absence (empty rhomboids) or in the
presence (black squares) of Herceptin.
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Figure 2 Binding of Erb-hcAb (A) and Erb-hRNase (B) to the ErbB2
extracellular domain (ECD) immobilised on plasmon resonance chips,
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saturated with Herceptin by two subsequent injections (marked by arrows)
before the addition of either Erb-hcAb (A) or Erb-hRNase (B) by two
subsequent injections (marked by arrows) over the chip. The insets show
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treatment for 72h at 371C with Herceptin (200nM), Erb-hcAb
(200nM) or with the combination of the two immunoagents at the
same concentrations. The combinatorial treatment clearly caused
an increased cell death than each antibody alone, and more
marked changes in cell morphology. Cells appeared to loose their
typical epithelial features and assume distorted, round-shaped
forms.
Effects of combination of Erb-hcAb and Herceptin on
ErbB2 levels
One possible mechanism underlying the antiproliferative effects of
anti-ErbB2 antibodies is the downregulation of the receptor.
Previous studies have shown that the effect of the Erbicin-derived
compact antibody on tumour cell growth correlates with the lower
ErbB2 levels generated by an increased receptor turnover as
triggered by antibody binding (De Lorenzo et al, 2005). On the
other hand, the high cytotoxicity of some anti-ErbB2 antibodies
has been correlated with an increased degradation of ErbB2
(Hurwitz et al, 1995; Klapper et al, 1997).
To test the effects on receptor downregulation of treatment with
combined antibodies, SKBR3 cells were metabolically labelled,
then treated for 16h with Erb-hcAb (200nM), or Herceptin
(200nM) or the combination of the two antibodies at the same
concentration. These concentrations were chosen to achieve the
degradation of the receptor, as previously reported (De Lorenzo
et al, 2005). The receptor was immunoprecipitated with an anti-
ErbB2 mAb from aliquots of cell lysates containing equal amounts
of radioactivity, and analysed by SDS–PAGE and autoradiography.
The results of the experiments, shown in Figure 5, indicated a
more severe reduction of the ErbB2 level when the immunoagents
were used in combination.
Densitometric evaluation of the data consistently indicated that
the level of ErbB2 was reduced by 40% after exposure of SKBR3
cells to either Herceptin or Erb-hcAb alone, and by more than 70%
when the two antibodies were used in combination. These results
suggest that both antibodies can effectively induce the down-
regulation of the receptor, but the combinatorial treatment is more
effective than the treatment with each single antibody.
Determination of apoptosis
To determine whether the combination of Erb-hcAb and Herceptin
induced a higher extent of apoptosis, we used annexin V to
measure the appearance of phosphatidylserine, a marker of
apoptosis, on the outer leaflet of the plasma membrane of SKBR3
cells. Cells were treated for 24h with Erb-hcAb, or Herceptin or a
combination of the two antibodies. The combinatorial treatment
induced a two-fold increase in the percentage of apoptotic cells
than that observed with each single antibody treatment. We found
25% of positive cells when the combined agents were used, and
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alone. This indicated that Erb-hcAb and Herceptin have additive
effects on growth inhibition through apoptosis.
Effects on cell survival of Erbicin-derived immunoagents
in combination with taxol or cis-platin
Previous reports (Ciardiello et al, 2000) have demonstrated that
ErbB2 overexpression confers to malignant cells chemoresistance to
anticancer drugs, as it activates the cycline-dependent kinase
inhibitor p21
Cip1, which in turn inhibits the p34
cdc2 kinase (Yu
et al, 1998). Thus, the activation of the latter kinase is required for
chemotherapy-induced apoptosis, and its inhibition can be
circumvented by antibody-mediated downregulation of the receptor.
On the basis of these observations, we investigated if down-
regulation of ErbB2 due to the action of the human anti-ErbB2 Erb-
hcAb could restore sensitivity to chemotherapy-induced apoptosis.
This would lead to a superior antitumour efficacy of the
chemotherapeutic drugs, when given in combination with Erb-hcAb.
Taxol and cis-platin are chemotherapeutic agents which have
already been shown to exert additive effects when used in
combination with Herceptin (Baselga et al, 1998). We thus
performed experiments to evaluate the effects of the combination
of Erb-hcAb with taxol or cis-platin. Cytotoxicity assays were
carried out on SKBR3 ErbB2-positive cells treated for 72h at 371C
with either taxol (8–16nM)o rcis-platin (10–35mM) or Erb-hcAb
(100nM) or with a combination of each drug and Erb-hcAb at the
same concentration. We found that the antitumour efficacy was
clearly superior when the chemotherapeutic drugs were given in
combination with Erb-hcAb (Figure 6A and B).
Similar experiments were performed with the chimaeric Erb-
hRNase. SKBR3 cells were treated for 72h at 371C with either taxol
(4–24nM)o rcis-platin (10–30mM) or Erb-hRNase (10nM) alone
or with a combination of each drug with Erb-hRNase at the same
concentration. As shown in Figure 6C and D, both taxol and
cis-platin displayed a much stronger cytotoxic effect when used in
combination with Erb-hRNase.
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or cis-platin with the Erbicin-derived immunoagents produced
additive effects, yielding synergistic interaction only when cis-platin
was used in combination with Erb-hRNase.
DISCUSSION
In the last few years, we have prepared and characterised new
human anti-ErbB2 immunoagents based on Erbicin, an scFv with
high affinity and selective cytotoxicity for ErbB2-positive cells (De
Lorenzo et al, 2002). They are, as described in Introduction: (1)
Erb-hRNase, an immuno-pro-toxin that contains a nontoxic
human RNase, which becomes toxic when tethered by the Erbicin
moiety inside tumour cells (De Lorenzo et al, 2004a); (2) Erb-
hcAb, a compact, reduced-size anti-ErbB2 antibody engineered
with Erbicin and the essential parts of a human immunoglobulin
(De Lorenzo et al, 2004b).
A rational approach to the evaluation of these new anti-ErbB2
immunoagents as potential antitumour agents is the comparison
of their properties with those of Herceptin (trastuzumab), now
established as a powerful therapeutic tool for ErbB2-overexpres-
sing breast cancer, and other carcinomas (Stebbing et al, 2000;
Scholl et al, 2001). As Herceptin has antitumour activity in only
one out of three of the patients, it is ineffective on ErbB2-low-
expressing tumour cells, and patients often develop resistance to
the drug after about one year of treatment, the attention has been
directed towards alternative strategies, such as the use of
combinatorial therapeutic protocols. Herceptin effectiveness has
been found to improve when administered in combination with
chemotherapeutic drugs, such as paclitaxel (Slamon et al, 2001;
Merlin et al, 2002) or other anti-ErbB2 antibodies (Spiridon et al,
2002; Willems et al, 2005). As for the latter approach, it is
necessary that the antibodies used in combination with Herceptin
are directed to epitopes on the target cells different from that
recognised by Herceptin.
We report here that the growth inhibition effects exerted by Erb-
hRNase and Erb-hcAb on ErbB2-positive cells are significantly
increased when used in combination with either chemotherapeutic
drugs, or Herceptin. The effectiveness of taxol and cis-platin was
found to increase more than two-fold when these drugs were used
in combination with either Erb-hRNase or Erb-hcAb. Likewise, the
cytotoxic action of Herceptin was enhanced by two- to three-fold
when ErbB2-positive cells were treated with Herceptin combined
with Erb-hRNase or Erb-hcAb.
The results obtained with Herceptin combined with the Erbicin-
based immunoagents can be explained by the finding, reported
here for the first time, that the epitope recognised by the Erbicin-
based immunoagents is different from that targeted by Herceptin.
This observation is supported by results from two different types
of binding tests: ELISA assays and plasmon resonance analyses.
The ability of the Erbicin-derived immunoagents to target an
ErbB2 epitope different from that targeted by Herceptin may also
explain recent, preliminary results from our laboratory (De
Lorenzo et al, unpublished), which suggest that these immunoa-
gents have no cardiotoxicity effects on treated cells, as Herceptin
does (Chien, 2000; Sparano, 2001), and appear to be cytotoxic also
on Herceptin-resistant cells (De Lorenzo et al, manuscript
submitted).
The investigated mechanistic features of the combined action of
Erb-hRNase or Erb-hcAb with Herceptin have revealed a highly
enhanced downregulation of the ErbB2 receptor, and clear signs of
apoptotic toxicity.
In conclusion, the results reported here indicate that Erbicin-
derived immunoagents have promising antitumour potential and
can be favourably used in combination with Herceptin and/or
conventional chemotherapeutic drugs.
ACKNOWLEDGEMENTS
This work was financially supported by MUR (Ministero dell’Uni-
versita ` e della Ricerca), Italy, and by Biotecnol, S.A., Portugal.
REFERENCES
Baselga J (2000) Current and planned clinical trials with trastuzumab
(Herceptin). Semin Oncol 27: 27–32
Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant
humanized anti-HER2 antibody (Herceptin) enhances the antitumor
activity of paclitaxel and doxorubicin against HER2/neu overexpressing
human breast cancer xenografts. Cancer Res 58: 2825–2831
Cardoso F, Piccart MJ, Durbecq V, Di Leo A (2002) Resistance to
trastuzumab: a necessary evil or a temporary challenge? Clin Breast
Cancer 3: 247–257; discussion 258–259
Chien KR (2000) Myocyte survival pathways and cardiomyopathy:
implications for trastuzumab cardiotoxicity. Semin Oncol 27: 9–14;
discussion 92–100
Ciardiello F, Caputo R, Pomatico G, De Laurentiis M, De Placido S,
Bianco AR, Tortora G (2000) Resistance to taxanes is induced by
c-erbB-2 overexpression in human MCF-10A mammary epithelial cells
and is blocked by combined treatment with an antisense oligonucleotide
targeting type I protein kinase A. Int J Cancer 85: 710–715
Cooke T, Reeves J, Lanigan A, Stanton P (2001) HER2 as a prognostic and
predictive marker for breast cancer. Ann Oncol 12: S23–S28
De Lorenzo C, Arciello A, Cozzolino R, Palmer DB, Laccetti P, Piccoli R,
D’Alessio G (2004a) A fully human antitumor immunoRNase selective
for ErbB-2-positive carcinomas. Cancer Res 64: 4870–4874
De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P, D’Alessio G
(2005) Biological properties of a human compact anti-ErbB2 antibody.
Carcinogenesis 26: 1890–1895
De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, D’Alessio G (2002) A new
human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8:
1710–1719
De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P,
Piccoli R, D’Alessio G (2004b) A human, compact, fully functional
anti-ErbB2 antibody as a novel antitumour agent. Br J Cancer 91:
1200–1204
Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE (1993) Monoclonal
antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell
growth. Br J Cancer 68: 1140–1145
Hurwitz E, Stancovski I, Sela M, Yarden Y (1995) Suppression and
promotion of tumor growth by monoclonal antibodies to ErbB-2
differentially correlate with cellular uptake. Proc Natl Acad Sci USA 92:
3353–3357
Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y,
Sela M (1997) A subclass of tumor-inhibitory monoclonal antibodies to
ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene
14: 2099–2109
Merlin JL, Barberi-Heyob M, Bachmann N (2002) In vitro comparative
evaluation of trastuzumab (Herceptin) combined with paclitaxel (Taxol)
or docetaxel (Taxotere) in HER2-expressing human breast cancer cell
lines. Ann Oncol 13: 1743–1748
Scholl S, Beuzeboc P, Pouillart P (2001) Targeting HER2 in other tumor
types. Ann Oncol 12: S81–S87
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A,
Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med 344:
783–792
Sparano JA (2001) Cardiac toxicity of trastuzumab (Herceptin): implica-
tions for the design of adjuvant trials. Semin Oncol 28: 20–27
Combinations of anti-ErbB2 immunoagents
C De Lorenzo et al
1359
British Journal of Cancer (2007) 97(10), 1354–1360 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sSpiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES (2002)
Targeting multiple Her-2 epitopes with monoclonal antibodies results in
improved antigrowth activity of a human breast cancer cell line in vitro
and in vivo. Clin Cancer Res 8: 1720–1730
Stebbing J, Copson E, O’Reilly S (2000) Herceptin (trastuzamab) in
advanced breast cancer. Cancer Treat Rev 26: 287–290
Willems A, Gauger K, Henrichs C, Harbeck N (2005) Antibody therapy for
breast cancer. Anticancer Res 25: 1483–1489
Yu D, Jing T, Liu B, Yao J, Tan M, McDonnell TJ, Hung MC (1998)
Overexpression of ErbB2 blocks Taxol-induced apoptosis by
upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 2:
581–591
Combinations of anti-ErbB2 immunoagents
C De Lorenzo et al
1360
British Journal of Cancer (2007) 97(10), 1354–1360 & 2007 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s